Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 15/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.40 |
| ▸ | CPB1 | P15086 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12333367 | 0.83 | CPB2 (0.53) | CPB2CDK5CDK5R1 | |
| SCHEMBL14650336 | 0.83 | CPB2 (0.53) | CPB2CDK5CDK5R1 | |
| SCHEMBL25626287 | 0.83 | CPB1 (0.41) | CPB2CPB1 | |
| SCHEMBL26246721 | 0.83 | CPB2 (0.38) | CPB2 | |
| SCHEMBL22920150 | 0.82 | CPB2 (0.54) | CPB2CDK5CDK5R1CPB1 | |
| SCHEMBL26246698 | 0.82 | CPB2 (0.48) | CPB2CDK5CDK5R1CPB1 | |
| SCHEMBL12333989 | 0.80 | CPB2 (0.55) | CPB2CDK5CDK5R1 | |
| SCHEMBL5470662 | 0.78 | CPB2 (0.54) | CPB2CDK5CDK5R1CPB1 | |
| SCHEMBL19141762 | 0.78 | CPB2 (0.54) | CPB2CDK5CDK5R1CPB1 | |
| SCHEMBL20080534 | 0.78 | CPB2 (0.54) | CPB2CDK5CDK5R1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| EP-3470399-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-10633346-B2 | Methods for producing optically active valeric acid derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-04-28 | — | — | US | disclosed |
| EP-3196192-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190055201-A1 | METHODS FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-02-21 | — | — | US | disclosed |
| US-9938242-B2 | Methods for producing optically active valeric acid derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-10 | — | — | US | disclosed |
| US-20180029993-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-01 | — | — | US | disclosed |
| US-20170291878-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-12 | — | — | US | disclosed |
| EP-3196193-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-07-26 | — | — | EP | disclosed |
| EP-3196192-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016043253-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVE | 第一三共株式会社 | 2016-03-24 | — | — | WO | disclosed |
| WO-2016043254-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVE | 第一三共株式会社 | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055201-A1 | METHODS FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVES | ALAD, GRHPR, ME1 | CPB2 1489/4885CDK5 2516/4885CDK5R1 3363/4885 |
| US-20180029993-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVE | ALAD, GRHPR, ME1 | CPB2 1887/4885CDK5 2527/4885CDK5R1 3315/4885 |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | CPB2 764/4885CDK5 3190/4885CDK5R1 2751/4885 |
| US-20170291878-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE VALERIC ACID DERIVATIVE | ALAD, GRHPR, ME1 | CPB2 1945/4885CDK5 2614/4885CDK5R1 3369/4885 |
| US-10633346-B2 | Methods for producing optically active valeric acid derivatives | ALAD, GRHPR, ME1 | CPB2 1489/4885CDK5 2516/4885CDK5R1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.